CINECA IRIS Institutional Research Information System

FERRARO, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.251
AS - Asia 1.618
EU - Europa 1.451
SA - Sud America 298
AF - Africa 169
OC - Oceania 21
Continente sconosciuto - Info sul continente non disponibili 2
Totale 5.810
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.189
SG - Singapore 516
IT - Italia 432
CN - Cina 392
HK - Hong Kong 266
SE - Svezia 258
BR - Brasile 239
DE - Germania 158
GB - Regno Unito 150
IN - India 121
VN - Vietnam 89
FI - Finlandia 79
BG - Bulgaria 78
CI - Costa d'Avorio 78
FR - Francia 73
TR - Turchia 45
JP - Giappone 43
NL - Olanda 43
RU - Federazione Russa 41
SN - Senegal 37
CA - Canada 31
ID - Indonesia 27
PL - Polonia 27
NG - Nigeria 23
KR - Corea 22
AR - Argentina 20
AU - Australia 20
MX - Messico 17
AT - Austria 16
EC - Ecuador 13
ES - Italia 13
PT - Portogallo 13
BD - Bangladesh 12
IQ - Iraq 12
IR - Iran 11
LT - Lituania 10
ZA - Sudafrica 10
CZ - Repubblica Ceca 9
IE - Irlanda 7
SA - Arabia Saudita 7
UA - Ucraina 7
VE - Venezuela 7
BE - Belgio 6
JO - Giordania 6
CL - Cile 5
CO - Colombia 5
GR - Grecia 5
PK - Pakistan 5
PY - Paraguay 5
RO - Romania 5
UZ - Uzbekistan 5
AZ - Azerbaigian 4
KZ - Kazakistan 4
MA - Marocco 4
PH - Filippine 4
AE - Emirati Arabi Uniti 3
CR - Costa Rica 3
DK - Danimarca 3
DZ - Algeria 3
EG - Egitto 3
HR - Croazia 3
IL - Israele 3
JM - Giamaica 3
LV - Lettonia 3
MY - Malesia 3
TH - Thailandia 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
AL - Albania 2
CH - Svizzera 2
ET - Etiopia 2
EU - Europa 2
GH - Ghana 2
GT - Guatemala 2
KE - Kenya 2
KG - Kirghizistan 2
NP - Nepal 2
PE - Perù 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
UY - Uruguay 2
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BN - Brunei Darussalam 1
CG - Congo 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GE - Georgia 1
HN - Honduras 1
IS - Islanda 1
JE - Jersey 1
LB - Libano 1
LK - Sri Lanka 1
MK - Macedonia 1
NZ - Nuova Zelanda 1
OM - Oman 1
PS - Palestinian Territory 1
SI - Slovenia 1
Totale 5.808
Salva come PNG Salva come JPEG
Città #
Ashburn 399
Singapore 297
Hong Kong 263
Santa Clara 237
Dallas 209
Chandler 148
Shanghai 144
Fairfield 91
Boardman 81
Abidjan 78
Florence 78
Sofia 78
New York 75
London 72
Munich 67
Los Angeles 65
Beijing 64
Princeton 50
Pisa 42
Serra 39
Helsinki 38
Dakar 37
Houston 36
Wilmington 36
Lawrence 34
Milan 33
Ho Chi Minh City 32
Istanbul 31
Turku 31
Woodbridge 30
Kent 27
Medford 27
Seattle 24
Lagos 23
Tokyo 23
Frankfurt am Main 22
Rome 22
Cambridge 21
Redwood City 21
Rio de Janeiro 20
Hyderabad 19
Massa 19
Mumbai 19
Hanoi 18
Hefei 18
Ann Arbor 17
Buffalo 17
Jakarta 17
Redondo Beach 17
Warsaw 17
Bremen 15
San Francisco 14
San Diego 13
Ogden 12
Denver 11
Fuzhou 11
Dong Ket 10
Lauterbourg 10
São Paulo 10
Washington 10
Chennai 9
Chicago 9
Düsseldorf 9
Belo Horizonte 8
Johannesburg 8
Livorno 8
Marseille 8
Mexico City 8
Nuremberg 8
Atlanta 7
Bengaluru 7
Brooklyn 7
Curitiba 7
Naples 7
Ottawa 7
Seoul 7
Vancouver 7
Amman 6
Amsterdam 6
Brussels 6
Cascina 6
Jeju City 6
Lappeenranta 6
Paris 6
Phoenix 6
Poplar 6
Quanzhou 6
Roubaix 6
Turin 6
Baia Mare 5
Dearborn 5
Duncan 5
New Malden 5
Prague 5
Quito 5
Torres Vedras 5
Baghdad 4
Baku 4
Birmingham 4
Brasília 4
Totale 3.693
Salva come PNG Salva come JPEG
Nome #
The Anti-TNF Drugs and the Risk of Lymphoma, Skin Cancer and Melanoma: A Signal Detection Analysis 184
Trajectories of oral budesonide use in Crohn's disease cohort of Tuscan patients (Italy) 170
Direct health care costs among patients with rheumatoid arthritis before and after the initiation of treatment with JAKi in Tuscany: The LEONARDO study 159
Longitudinal adherence trajectories to biologic disease modifying anti-rheumatic drugs in Tuscany, Italy 153
Adherence to mesalazine and identification of patients with ulcerative colitis in healthcare administrative databases of Tuscany (Italy) 146
Antibiotic Drugs and Unresolved Sensory Side Effects: Analysis of Eudravigilance Database of Suspected Adverse Drug Reaction Reports 140
Validation test for algorithms to identify rheumatoid arthritis patients in the Tuscan healthcare administrative databases 137
Utilisation patterns and clinical impact of the introduction of infliximab-biosimilar in Tuscany, Italy: real world evidence following the recommendation of switching for non-medical reasons 136
Diagnostic delay, effectiveness and safety outcomes in a real-world cohort of patients with Crohn's disease: Data from administrative databases in Tuscany, Italy 133
Potential Direct Costs of Adverse Drug Events and Possible Cost Savings Achievable by their Prevention in Tuscany, Italy: A Model-Based Analysis 131
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline 131
Is There a Risk of Lymphoma Associated With Anti-tumor Necrosis Factor Drugs in Patients With Inflammatory Bowel Disease? A Systematic Review of Observational Studies 130
Olfactory and gustatory impairments in COVID-19 patients: Role in early diagnosis and interferences by concomitant drugs 130
Raynaud’s Phenomenon Associated with Calcitonin Gene-Related Peptide (CGRP) Antagonists: a Disproportionality Analysis on VigiBase 126
Time to biologic treatment and to total colectomy associated with diagnostic delay in ulcerative colitis: Analysis of an Italian regional administrative healthcare database 122
Listening Social Media for Pharmacovigilance Objectives: Which Usefulness? 122
The usefulness of listening social media for pharmacovigilance purposes: a systematic review 119
Trajectories of use of biologic disease modifying antirheumatic drugs in rheumatoid arthritis: A cohort study of Tuscan patients, Italy 119
Analysis of fatal adverse drug events recorded in several Italian emergency departments (the MEREAFaPS study) 119
Assessing disease activity of rheumatoid arthritis patients and drug-utilization patterns of biologic disease-modifying antirheumatic drugs in the Tuscany region, Italy 118
Unresolved gustatory, olfactory and auditory adverse drug reactions to antibiotic drugs: a survey of spontaneous reporting to Eudravigilance 116
Utilization patterns and healthcare accesses of JAKi used in rheumatoid arthritis patients in Tuscany: The LEONARDO study 116
Anticoagulant Therapy and Risk of Bleeding in Patients with Atrial Fibrillation of Four Italian Regions: The TYRION Study 116
Trajectories of Adherence to Biologic Disease-Modifying Anti-Rheumatic Drugs in Tuscan Administrative Databases: The Pathfinder Study 112
Recommendations by the Tuscan Health Authority to Use Infliximab-Biosimilar in the Clinical Practice: Safety Impact 111
Disproportionality Analysis of ‘‘Early-Onset’’ Tardive Dyskinesia Stratified by Time to Onset Using FAERS Database. 105
An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future 105
Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients 103
THE ECONOMIC IMPACT OF THE INTRODUCTION OF INFLIXIMAB-BIOSIMILAR: AN EMPIRICAL ANALYSIS USING THE TUSCANY HEALTHCARE ADMINISTRATIVE DATABASES 103
Validation of algorithms for selecting rheumatoid arthritis patients in the Tuscan healthcare administrative databases 100
Anti-tumor Necrosis Factor Drugs and Risk of Lymphoma in Patients with Inflammatory Bowel Disease 98
Exploring the relationship between utilization patterns of biologic disease-modifying anti-rheumatic drugs and disease activity in rheumatoid arthritis patients 96
Anticoagulant Therapy in Patients with Atrial Fibrillation and Risk of Bleeding: Interim Analysis: Tyrion Study 96
The Economic Impact of the Introduction of Infliximab-Biosimilar: Preliminary Results from a Study on Rheumatologic Patients in Tuscany, Italy 95
Discontinuation rate to biologic and targeted synthetic DMARDs in rheumatoid arthritis patients: Systematic review and meta-analysis 94
Erratum to: Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System (Drug Safety, (2023), 46, 3, (283-295), 10.1007/s40264-022-01269-x) 93
A Model-Based Analysis on Direct Costs of Adverse Drug Events and Related Cost-Savings Achievable by their Prevention in Tuscany, Italy 92
The Impact of the COVID-19 “Infodemic” on Drug-Utilization Behaviors: Implications for Pharmacovigilance 91
Fatal Fat Overload Syndrome Following Intravenous Lipid Emulsion Administration as Antidote in Suspected Anesthetic Intoxication: A Fatal Medication Error. 87
Switching from infliximab-originator to infliximab-biosimilar in rheumatologic patients: The clinical impact in Tuscan Region, Italy 86
Analysis of the Drug Related Emergency Department Admissions in Tuscany: The FARO Project 85
Risk of hospitalisation associated with benzodiazepines and z-drugs in Italy: a nationwide multicentre study in emergency departments 85
Evaluation of drug-utilization and healthcare facilities use in patients with ulcerative colitis and treated with biologic therapy using data of an Italian healthcare administrative database: Results from michelangelo study 80
Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis 79
Assessment of Healthcare Facilities Associated with JAKi Drugs Used in Rheumatoid Arthritis Patients in Tuscany, Italy: The LEONARDO 71
Potential missed diagnoses of Crohn's disease in tertiary care: impact on drug utilization and healthcare facilities use 71
Oral Presentation: Signal of Hypertension Associated with COVID-19 Vaccination: VigiBase (R) Data and Evidence from Real World 71
Supporting the Spontaneous Reporting by Health Care Professionals of the University Hospital of Pisa, Italy: a Pilot Project from the Unit of Adverse Drug Reactions Monitoring 67
Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence 63
Communicating Drug Safety 61
Lessons learnt from the preclinical discovery and development of ensitrelvir as a COVID-19 therapeutic option 59
Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fall 56
Oral Presentation: Accesses to Emergency Department and Hospitalizations in New Users of Biologic Therapies for Ulcerative Colitis in Tuscany: The MICHELANGELO Study 56
null 56
COVID-19 Vaccines and Thromboembolic Events with Thrombocytopenia: Data from Italian Pharmacovigilance Public Database 55
Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data 51
Signals of Possibly Persistent Gustatory, Olfactory and Auditory Adverse Drug Reactions to Antibiotic Drugs: A Disproportionality Analysis Using the EudraVigilance Database 50
Unresolved Gustatory, Olfactory and Auditory Adverse Drug Reactions to Antibiotic Drugs: A Signal Detection Analysis on Publicly Accessible Eudravigilance Data 43
Cases of acquired hemophilia A following COVID‐19 vaccines: Cogent safety signal or possible reporting/detection bias? Preliminary evidence from Tuscany, Italy 14
Totale 5.913
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.850
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.850
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021139 0 0 0 0 0 0 7 3 15 0 16 98
2021/2022621 12 16 70 75 89 88 25 32 31 19 44 120
2022/2023818 110 156 57 45 65 68 27 32 179 1 75 3
2023/2024682 17 34 42 16 65 99 85 48 38 37 104 97
2024/20252.210 38 87 102 176 149 263 188 78 224 261 247 397
2025/20261.270 236 186 280 251 292 25 0 0 0 0 0 0
Totale 5.913